Vertex Pharmaceuticals Inc
VRTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000875320
In the last 90 days, Vertex Pharmaceuticals Inc insiders filed 0 open-market purchases and 3 sales; 1,763 institutions reported holding it in 13F filings for Q2 2026, worth $119.7B in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Vertex Pharmaceuticals Inc as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 1,127
- +33 vs. Q2 2022
- Shares held
- 237.2M
- +1.97M (+0.8%) vs. Q2 2022
- Total value
- $68.5B
- +$2.47B (+3.7%) vs. Q2 2022
- New holders
- 113
- 433 more added
- Sold out
- 80
- 409 more reduced
15 institutions that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VRTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1,763 | $119.7B |
| Q1 2026 | 1,698 | $106.1B |
| Q4 2025 | 1,671 | $109.5B |
| Q3 2025 | 1,523 | $90.8B |
| Q2 2025 | 1,564 | $107.2B |
| Q1 2025 | 1,618 | $116.3B |
| Q4 2024 | 1,563 | $95.2B |
| Q3 2024 | 1,551 | $109.1B |
| Q2 2024 | 1,551 | $109.9B |
| Q1 2024 | 1,497 | $98.0B |
| Q4 2023 | 1,442 | $95.7B |
| Q3 2023 | 1,280 | $81.9B |
| Q2 2023 | 1,288 | $83.3B |
| Q1 2023 | 1,213 | $75.0B |
| Q4 2022 | 1,225 | $68.3B |
| Q3 2022 | 1,128 | $68.5B |
| Q2 2022 | 1,110 | $66.1B |
| Q1 2022 | 1,073 | $60.9B |
| Q4 2021 | 1,034 | $50.4B |
| Q3 2021 | 936 | $41.9B |
| Q2 2021 | 979 | $46.8B |
| Q1 2021 | 1,000 | $50.6B |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Vertex Pharmaceuticals Inc; share changes are against Q2 2022.